The unique biology of lymphatic edema

Lymphatic Research and Biology

Volumn 7, Issue 2, 2009, Pages 97-100

  Rockson, Stanley G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; MONOCLONAL ANTIBODY; NEUROPILIN 2; NEUTRALIZING ANTIBODY; PODOPLANIN; PROTEIN KINASE SYK; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADIPOSE TISSUE; ADJUSTMENT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL; BODY IMAGE; BREAST CANCER; CANCER SURVIVOR; CAPILLARY; CHRONIC DISEASE; COMPRESSION THERAPY; EARLY DIAGNOSIS; FEAR; FILARIASIS; FLUID BALANCE; HISTOPATHOLOGY; HUMAN; IATROGENIC DISEASE; IMPEDANCE; LIPOSUCTION; LYMPH FLOW; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; LYMPHATIC SYSTEM DISEASE; LYMPHEDEMA; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; SELF ESTEEM; SHORT SURVEY; SIGNAL TRANSDUCTION; SOCIAL ASPECT; SOFT TISSUE INFECTION;

ANIMALS; HUMANS; LYMPHATIC VESSELS; LYMPHEDEMA;

EID: 67650787355     PISSN: 15396851     EISSN: None     Source Type: Journal    
DOI: 10.1089/lrb.2009.7202     Document Type: Short Survey

References (37)

1. Rockson SG. Lymphedema. Am J Med 2001;110:288-295.
2. Rockson SG. How can lymphatic research influence lymphatic education? Lymphat Res Biol 2004;2:67-68.
3. Rockson SG, Granger DN, Skeff KM, Chaite W. Lymphatic biology and disease: Is it being taught? Who is listening? Lymphat Res Biol 2004;2:86-95.
4. Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 2008;52:799-806.
5. Oliver G. Lymphatic vasculature development. Nat Rev Immunol 2004;4:35-45.
6. Saaristo A, Karkkainen M, Alitalo K. Insights into the molecular pathogenesis and targeted treatment of lymphede-ma. Ann NY Acad Sci 2002;979:94-110.
7. An A, Rockson SG. The potential for molecular treatment strategies in lymphatic disease. Lymphat Res Biol 2004;2:173-181.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
9. Nakamura K, Rockson SG. Molecular targets for therapeutic lymphangiogenesis in lymphatic dysfunction and disease. Lymphat Res Biol 2008;6:181-189.
10. Ferrell RE, Kimak MA, Lawrence EC, Finegold DN. Candidate gene analysis in primary lymphedema. Lymphat Res Biol 2008;6:69-76.
11. Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, Baty CJ, Ferrell RE. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 2008;6:65-68.
12. Butler MG, Dagenais SL, Rockson SG, Glover TW. A novel VEGFR3 mutation causes Milroy disease. Am J Med Genet A 2007;143A:1212-1217.
13. Drivdal M, Trydal T, Hagve TA, Bergstad I, Aagenaes O. Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/ Aagenaes syndrome). Scand J Gastroenterol 2006;41:465-471.
14. Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Car-dona G. Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer 2001;92:1783-1787.
15. Rockson SG. Precipitating factors in lymphedema: Myths and realities. Cancer 1998;83:2814-2816.
16. Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999;177:184-187; discussion 188.
17. Szuba A, Shin WS, Strauss HW, Rockson S. The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med 2003;44:43-57.
18. Stemmer R. [A clinical symptom for the early and differential diagnosis of lymphedema]. Vasa 1976;5:261-262.
19. Cornish B. Bioimpedance analysis: Scientific background. Lymphat Res Biol 2006;4:47-50.
20. Ward LC. Bioelectrical impedance analysis: Proven utility in lymphedema risk assessment and therapeutic monitoring. Lymphat Res Biol 2006;4:51-56.
21. Szuba A, Cooke JP, Yousuf S, Rockson SG. Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. Am J Med 2000;109:296-300.
22. Olszewski WL, Engeset A. Intrinsic contractility of prenodal lymph vessels and lymph flow in human leg. Am J Physiol. 1980;239:H775-783.
23. Wilburn O, Wilburn P, Rockson SG. A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412]. BMC Cancer 2006;6:84.
24. Beilhack A, Rockson SG. Immune traffic: A functional overview. Lymphat Res Biol 2003;1:219-234.
25. Johnson LA, Jackson DG. Cell traffic and the lymphatic en-dothelium. Ann NY Acad Sci 2008;1131:119-133.
26. Tabibiazar R, Cheung L, Han J, Swanson J, Beilhack A, An A, Dadras SS, Rockson N, Joshi S, Wagner R, Rockson SG. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med 2006;3:e254.
27. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002;21:1505-1513.
28. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999;98:769-778.
29. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet 2005;37:1072-1081.
30. Brorson H, Ohlin K, Olsson G, Nilsson M. Adipose tissue dominates chronic arm lymphedema following breast cancer: An analysis using volume rendered CT images. Lymphat Res Biol. 2006;4:199-210.
31. Brorson H, Ohlin K, Olsson G, Karlsson M. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol 2009;7:3-10.
32. Brorson H, Svensson H. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. Plast Reconstr Surg 1998;102:1058-1067; discussion 1068.
33. Brorson H. Liposuction in arm lymphedema treatment. Scand J Surg 2003;92:287-295.
34. Cheung L, Han J, Beilhack A, Joshi S, Wilburn P, Dua A, An A, Rockson SG. An experimental model for the study of lymphedema and its response to therapeutic lymphangio-genesis. BioDrugs 2006;20:363-370.
35. Schneider M, Ny A, Ruiz de Almodovar C, Carmeliet P. A new mouse model to study acquired lymphedema. PLoS Med 2006;3:e264.
36. Jin DP, An A, Liu J, Nakamura K, Rockson SG. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: Immunohistochemical and molecular characterization. Lymphat Res Biol 2009;7:47-57.
37. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006;95: 1611-1625.